PDCD1 and melanoma: Response rates to anti-PD-1 plus anti-IDO1 appeared higher than with anti-PD-1 alone in early trials, however, the pivotal phase III trial in melanoma failed to meet its endpoint and several large trials, including those for NSCLC, were subsequently scaled back or halted [49].